康华生物(300841) - 2025 Q3 - 季度财报

Important Notice This section outlines the company's declarations regarding the report's accuracy and completeness, confirming the financial information is unaudited Report Statement and Audit Status The board of directors, supervisory board, and senior management guarantee the report's truthfulness, accuracy, and completeness; financial information is declared true, complete, and unaudited - The board of directors, supervisory board, and senior management guarantee the report's truthfulness, accuracy, and completeness, and assume legal responsibility[4] - The company's head, chief accountant, and head of accounting department declare the financial information to be true, accurate, and complete[4] - The third-quarter financial report is unaudited[5] I. Key Financial Data This section presents the company's key accounting data and financial indicators, highlighting significant changes in profitability, assets, liabilities, and cash flows 1. Key Accounting Data and Financial Indicators Operating revenue increased year-on-year, but net profit attributable to shareholders and non-recurring net profit significantly decreased, with larger declines in profitability and net operating cash flow from year-to-date Key Financial Indicators for the Current Period and Year-to-Date | Indicator | Current Period (CNY) | YoY Change (%) | Year-to-Date (CNY) | YoY Change Year-to-Date (%) | | :--- | :--- | :--- | :--- | :--- | | Operating Revenue | 356,143,615.07 | 11.54% | 840,062,581.82 | -20.78% | | Net Profit Attributable to Shareholders of Listed Company | 74,590,140.27 | -24.92% | 189,110,720.76 | -53.41% | | Net Profit Attributable to Shareholders of Listed Company Excluding Non-Recurring Gains and Losses | 71,764,743.04 | -30.82% | 183,318,264.19 | -55.57% | | Net Cash Flow from Operating Activities | -- | -- | 153,725,204.88 | -39.22% | | Basic Earnings Per Share (CNY/share) | 0.5740 | -24.49% | 1.4553 | -52.59% | | Diluted Earnings Per Share (CNY/share) | 0.5740 | -24.49% | 1.4553 | -52.59% | | Weighted Average Return on Net Assets | 2.15% | -0.74% | 5.43% | -6.11% | Balance Sheet Indicators at Period End vs. Prior Year End | Indicator | Current Period End (CNY) | Prior Year End (CNY) | Change from Prior Year End (%) | | :--- | :--- | :--- | :--- | | Total Assets | 3,937,496,245.21 | 4,027,582,273.97 | -2.24% | | Owners' Equity Attributable to Shareholders of Listed Company | 3,506,672,518.04 | 3,447,508,696.28 | 1.72% | - Excluding prior year's reclassified hexavalent norovirus vaccine overseas licensing revenue, year-to-date operating revenue decreased by 11.96%, net profit by 40.08%, and non-recurring net profit by 43.12%[6] 2. Non-Recurring Gains and Losses Items and Amounts Total non-recurring gains and losses for the current period were CNY 2.83 million and CNY 5.79 million year-to-date, mainly from government grants, fair value changes of financial assets, and investment income from associates Non-Recurring Gains and Losses Items and Amounts | Item | Current Period Amount (CNY) | Year-to-Date Amount (CNY) | Description | | :--- | :--- | :--- | :--- | | Gains or losses from disposal of non-current assets | 0.00 | -8,912.45 | | | Government grants recognized in current profit or loss | 258,911.37 | 1,795,232.74 | | | Gains or losses from changes in fair value of financial assets and liabilities, and investment income from disposal of financial assets and liabilities | 2,900,708.16 | 4,908,108.17 | Fair value changes of associates, wealth management income, and investment income from associates | | Other non-operating income and expenses apart from the above | -6,252.67 | -46,493.28 | | | Less: Income tax impact | 327,969.63 | 855,478.61 | | | Total | 2,825,397.23 | 5,792,456.57 | -- | 3. Analysis of Changes in Key Accounting Data and Financial Indicators Significant changes occurred across balance sheet, income statement, and cash flow statement items, with notable shifts in receivables, deferred tax assets, construction in progress, investment income, impairment losses, and cash flows from operations and financing Key Changes in Consolidated Balance Sheet Items and Reasons (Period End vs. Year Start) | Balance Sheet Item | Change (%) | Primary Reason for Change | | :--- | :--- | :--- | | Other Receivables | 78.21% | Due to accrual of employee compensation | | Other Current Assets | 60.90% | Due to increase in estimated return receivables | | Construction in Progress | -100.00% | Due to completion and capitalization of construction in progress | | Deferred Income Tax Assets | 100.08% | Due to accrual of credit impairment losses and inventory depreciation reserves | | Notes Payable | -100.00% | Due to payment of matured notes | | Accounts Payable | -60.19% | Due to payment of procurement settlements | | Contract Liabilities | -56.07% | Due to decrease in advances from customers | | Employee Compensation Payable | -31.52% | Due to payment of employee compensation for 2024 | | Taxes Payable | 99.57% | Due to income tax adjustments | | Other Payables | -34.40% | Due to settlement of promotion fees and engineering equipment payments | | Other Current Liabilities | -56.07% | Due to decrease in contract liabilities | | Deferred Income | 35.75% | Due to receipt of asset-related government grants | | Treasury Stock | -100.00% | Due to cancellation of treasury stock | Key Changes in Consolidated Income Statement Items and Reasons (Year-to-Date vs. Prior Year Period) | Income Statement Item | Change (%) | Primary Reason for Change | | :--- | :--- | :--- | | Financial Expenses | 51.36% | Due to decrease in interest income | | Investment Income (Losses indicated by "-") | 214.41% | Due to investment income from associates | | Gains from Changes in Fair Value (Losses indicated by "-") | 123.70% | Due to fair value changes of associates | | Credit Impairment Losses (Losses indicated by "-") | 63.03% | Due to decrease in bad debt provisions for accounts receivable and other receivables | | Asset Impairment Losses (Losses indicated by "-") | -438.17% | Due to impairment provisions made as per regulations | | Gains from Asset Disposal (Losses indicated by "-") | 99.50% | Due to decrease in asset disposals | | Non-Operating Expenses | -78.29% | Due to decrease in donation expenses | | Income Tax Expense | -42.44% | Due to decrease in operating profit | Key Changes in Consolidated Cash Flow Statement Items and Reasons (Year-to-Date vs. Prior Year Period) | Cash Flow Statement Item | Change (%) | Primary Reason for Change | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | -39.22% | Due to reduced product sales collections and overseas licensing revenue collections | | Net Cash Flow from Investing Activities | 7.27% | Due to reduced investment in fixed assets | | Net Cash Flow from Financing Activities | 60.48% | Due to reduced share repurchases and dividend distributions | II. Shareholder Information This section details the company's common and preferred shareholder structure, including top shareholders, their holdings, and changes in restricted shares 1. Common Shareholder Holdings and Top Ten Shareholders As of the reporting period end, the company had 18,290 common shareholders, with Aokang Group and Wang Zhentao as parties acting in concert among the top ten, holding significant pledged stakes - As of the end of the reporting period, the total number of common shareholders was 18,290, with no preferred shareholders whose voting rights have been restored[14] Top 10 Shareholder Holdings | Shareholder Name | Shareholder Nature | Holding Ratio (%) | Number of Shares Held (shares) | Number of Restricted Shares Held (shares) | Pledge, Mark or Freeze Status (Status/Number of Shares) | | :--- | :--- | :--- | :--- | :--- | :--- | | Aokang Group Co., Ltd. | Domestic Non-State-Owned Legal Person | 12.55% | 16,305,468 | 0 | Pledged/11,725,000 | |